Crossmark

Placebo response in RCT for antidepressant may not always be the ‘villain’ to fight: are KOR antagonists possibly affecting the intrinsic placebo response?

Crossref DOI link: https://doi.org/10.1038/s41386-024-01878-3

Published Online: 2024-05-23

Published Print: 2024-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Merlo Pich, Emilio https://orcid.org/0000-0001-5478-235X
License Information

Text and Data Mining valid from 2024-05-23

Version of Record valid from 2024-05-23
More Information

Article History

Received: 15 April 2024

Accepted: 24 April 2024

First Online: 23 May 2024

Competing interests

: Emilio Merlo Pich was the Global Head of R&D in Alfasigma SPA (I) from 2019 to 2022. In 2023, as CEO of Gelf Heath srl, he was consultant for Relmada Therapeutics Inc. (USA), Centessa Pharmaceuticals (USA), Novavido (I), and G-Factor (I). In 2024 he was consultant for Novavido (I), G-Factor (I), IFAB (I), BIP GROUP (I) and Tarnanai (CH).

Document is current

Any future updates will be listed below